Compare ADMA Biologics Inc (ADMA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? ADMA Biologics Inc trades at $9.16 (market cap $2.13B), while YieldMax TSLA Option Income Strategy ETF trades at $26.91. Which is the better fit depends on your goals.
| ADMA | TSLY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $48.25 |
52-Week Low | $7.60 | $26.16 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TSLY trades at $28.45, up 6.04% with a bearish technical signal from moving averages. The ETF generates income through synthetic TSLA exposure and covered call strategies, currently yielding an annualized 52.65%. Recent weekly dividend announcements from YieldMax highlight the fund's income-focused strategy, though distributions are primarily return of capital.
The outlook remains cautious given technical bearishness and capped upside from covered call strategies. Key risks include TSLA volatility exposure and concentration in aggressive options strategies. Investors seeking high income may find value, but should monitor underlying TSLA performance and distribution sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
